Category Archives: Pr Newswire

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Research Published in THE LANCET’s eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announces the peer-reviewed publication on the Phase II ChronEx study assessing the safety […]

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., […]

Pan Pacific Hotels Group Extends Presence in Japan through Continued Strategic Partnership with Tokyu Hotels

THE HOTEL HIGASHIYAMA KYOTO TOKYU, A Pan Pacific Hotel, will be added to group’s portfolio in Japan from 10 January 2025 SINGAPORE, July 29, 2024 /PRNewswire/ — Pan Pacific Hotels Group debuts in Kyoto with the signing of a strategic partnership with Tokyu Hotels following the launch of BELLUSTAR TOKYO, A Pan Pacific Hotel and HOTEL […]

Xuan Wu Cloud Announces Positive Profit Alert

GUANGZHOU, China, July 29, 2024 /PRNewswire/ — Xuan Wu Cloud Technology Holdings Limited (“Xuan Wu Cloud” or the “Group,” stock code: 2392.HK), a leading intelligent CRM service provider in China, today announced its positive alert for the six months ended June 30, 2024. Based on the information currently available to the Board and a preliminary […]

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year Net Profit Attributable to the Owners of the Company Reached RMB4,240 Million, and Diluted Earnings per Share (EPS) of RMB1.45 for the First Half  Adjusted Non-IFRS […]

UNLIMEAT’s K-Vegan Products Debut at The GIANT Company

UNLIMEAT’s Plant-Based Korean Meals Across 149 GIANT and MARTIN’S Stores.   The product lineup includes plant-based meat and convenient meals like frozen kimbap products. NEW YORK, July 29, 2024 /PRNewswire/ — UNLIMEAT, a pioneering Korean plant-based food brand, has announced the launch of five products in 149 GIANT and MARTIN’S stores. UNLIMEAT’s K-Vegan Line at GIANT […]

EXPOSURE TO WILDFIRE SMOKE GREATLY RAISES RISK OF DEMENTIA DIAGNOSIS

Key Takeaways Wildfire smoke may be particularly hazardous to brain health, according to a 10-year study of more than 1.2 million southern Californians.  Exposure to wildfire smoke increases the risk of being diagnosed with dementia more than other forms of air pollution.   The risk of exposure to fine particulate matter (PM2.5) air pollution is much […]

Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer’s Association Conference

Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer’s disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups Benefits of blarcamesine on both amyloid-beta and brain volume, two underlying pathological hallmarks of Alzheimer’s disease […]

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

– Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease – – Study meets its key objectives to advance data supporting favorable benefit/risk profile, support target engagement, and provide additional support for the efficacy profile of Lomecel-B™ – – […]

Regeneration Biomedical to Present Data on First Two Subjects in a Phase I Clinical Trial of Stem Cell Therapy delivered directly into the brains of Patients with Alzheimer’s Disease

Wnt-activated, autologous, expanded, adipose-derived stem cells administered directly into lateral ventricles of the brain via Ommaya reservoir implanted under the scalp to bypass blood brain barrier Data to be presented at the Alzheimer’s Association International Conference (AAIC), 8 a.m. EDT, July 28, 2024 NEWPORT BEACH, Calif., July 28, 2024 (GLOBE NEWSWIRE) — Regeneration Biomedical, Inc. […]